Navigation Links
C3i and Bristol-Myers Squibb to Discuss the Effects of Oracle Clinical 4.5.3 Zero Footprint on Support Services at the Oracle Health Sciences User Group Conference
Date:10/5/2010

SAN ANTONIO, Texas, Oct. 5 /PRNewswire/ -- C3i, the leader in technology services for the life sciences industry, and Bristol-Myers Squibb (BMS), a leading global biopharmaceutical company, will deliver a joint presentation discussing the advantages realized from upgrading to the newest version of Oracle Clinical/Remote Data Capture (OCRDC) software. The presentation will take place in October during the Oracle Health Sciences User Group conference (OHSUG) in San Antonio, TX October 10-13.

The presentation, titled "The Direct and Indirect Effects Upgrading to Zero Footprint has on Clinical Services", investigates several support areas of interest including site assessment, connectivity, laptop provisioning and software issues. Based on quantitative data gathered from BMS operations, Darlene Kalinowski, Associate Director, EDC Operations at BMS and Warren Ryanes, Account Director at C3i will demonstrate the benefits to clinical trial sponsors of upgrading to OCRDC 4.5.3. The "before" and "after" case study will show improvements in material, time and costs. The two presenters will highlight how a "zero footprint" and a decrease in 3rd party plug-ins results in cost savings in areas as diverse as shipping and connectivity, and in fewer support cases related to data entry, navigation, and reports.

"The Oracle Health Sciences User Group conference is a great place to exchange knowledge on Oracle products and related services .We are excited to share the positive experience of BMS with our colleagues from the industry," said Darlene Kalinowski. Warren Ryanes added: "BMS is a great partner. C3i is delighted to have the opportunity work with Darlene and her team to achieve such excellent results."

About C3i: Headquartered in Morristown, New Jersey, C3i Inc. has global operations centers in the United States, India and Bulgaria. Their 1000 employees provide consulting, systems implementation, technology training, multi-lingual help desk, ha
'/>"/>

SOURCE C3i
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
2. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
3. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
4. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
5. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
6. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
7. [video] Jacques Tizabi, CEO of Universal Detection Technology Discusses Latest Purchase Order on WallSt.nets 3-Minute Press Show
8. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
9. VentriPoint Diagnostics Files Management Discussion and Analysis, Unaudited Financial Results for 2Q 2008
10. Anesiva Announces Conference Call and Webcast to Discuss Updates to Corporate Strategy and Milestones
11. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013 Cempra, Inc. (Nasdaq: ... differentiated antibiotics to meet critical medical needs in ... it presented data at the American Thoracic Society ... demonstrating the antibacterial and enhanced immunomodulatory ... Phase 2 clinical trial in outpatients with community ...
(Date:5/20/2013)... May 20, 2013 Researchers from the ... connection between lower back pain, and the acne causing P.acnes ... the system the bacteria seek out oxygen deprived location to ... the spinal column, P.acnes has the ability to live in ... Fernando Perez, a spokesman for “ The best acne treatment ...
(Date:5/20/2013)... May 20, 2013 In Early 2013, ... field of biotoxin related illnesses , announced his vision ... able to advance his protocol for treating Chronic Inflammatory ... the third physician to achieve certification in the Shoemaker ... able to practice the Shoemaker Protocol in other parts ...
(Date:5/17/2013)... Topricin Pain Relief and Healing Cream, ... among nationally recommended over-the-counter (OTC) health products 2012 ... News" Health in collaboration with "Pharmacy Times." ... Pharmacists Recommended designation” in the “Topical Analgesics” category, ... is the only homeopathic formula to earn that ...
Breaking Biology Technology:Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2Adult Acne Treatment, Probiotic Action Shares New Insight How Treating Acne May Help Reduce Body Pain 2Dr. Ritchie Shoemaker Certifies Third Physician in His Treatment Protocol for Chronic Inflammatory Response Syndrome (CIRS) 2Pharmacists' Picks: Topical BioMedics' Topricin Listed on Top Recommended OTC Health Products 2
... Milestone triggers $10 million payment from Eli Lilly ... - BioMS Medical Corp. (TSX:,MS), a leading developer ... that the independent Drug Safety Monitoring Board (DSMB) ... analysis of efficacy,and safety and has recommended that ...
... Scotland, S.D. to start in Q4 ,08. , ... ... Coalition for Ethanol conference, http://www.poet.com [POET] announced that construction ... facility later this year. The pilot plant will be adjacent to ...
... ATSI ), manufacturer and marketer of state-of-the-art ... at the Fourth,Annual Noble Financial Equity Conference at ... Financial Officer of ATS Medical, will,present at 2:30 ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ), Attendance at ...
Cached Biology Technology:BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis 2BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis 3BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis 4POET Announces That Cellulosic Ethanol Pilot Facility Will Be Operational This Year 2POET Announces That Cellulosic Ethanol Pilot Facility Will Be Operational This Year 3ATS Medical to Participate at the Fourth Annual Noble Financial Equity Conference 2
(Date:5/16/2013)... Access to Research Careers) Program has announced the ... Biology (SDB) 72nd Annual Meeting in Cancun, Mexico ... to promote the entry of students, postdoctorates and ... the basic science community and to encourage the ... Annual Meeting. , Awards are given to poster/platform ...
(Date:5/16/2013)... BOSTON The endothelium, the cellular layer lining ... just a few hundred nanometers in thickness, this ... stretch and tissue compression to create a unique ... necessary to partition tissues from the body,s circulatory ... when the barrier must be physically breached ...
(Date:5/16/2013)... are about 23 million years old give unprecedented ... order, one of the most species-rich groups among ... paleontologist Professor Bettina Reichenbacher from the Division of ... and Environmental Sciences at Ludwig-Maximilians-Universitaet (LMU) in Munich ... fish fossils which they assign to the group ...
Breaking Biology News(10 mins):Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 3
... Testing people for heart disease might be just a ... created by a team of researchers from Harvard and Northeastern ... The FASEB Journal ( http://www.fasebj.org ), they describe ... cells needed to build vascular tissue, called endothelial progenitor cells, ...
... Boston, MA June 1, 2009 REGiMMUNE Corporation ... combination with a low-dose of Sirolimus, demonstrated enhanced efficacy ... and acute Graft-versus-Host disease (GvHD). This data is ... Induction by a Liposomal Formulation of KRN7000 (RGI-2001) Alone ...
... years modeled how different species are likely to respond ... populations within a species and the interactions between species, ... June issue of BioScience , by Eric Post ... these limitations can be avoided. Their approach, which relies ...
Cached Biology News:New device detects heart disease using less than one drop of blood 2REGiMMUNE presents enhanced efficacy data in preclinical transplantation models 2